Dr. Michael Wach

About Dr. Wach

Dr. Michael Wach offers surgical care for peritoneal mesothelioma and other GI cancer patients within Moffitt Cancer Center’s Department of Gastrointestinal Oncology. His expertise includes tumor-removing or cytoreductive surgery, HIPEC and advanced treatment techniques to address asbestos-related tumors. 

He works closely with a multidisciplinary team to improve diagnosis, treatment and patient support. Dr. Wach focuses on offering tailored surgery combined with chemotherapy to improve survival and quality of life for people diagnosed with mesothelioma.

Close Button

Full Name

Diagnosis Please Select Mesothelioma Asbestosis Lung Cancer No Diagnosis Other Unknown

Zip Code

Email

Phone Number

Preferred Method of Contact Please Select Call Text

Message

Full Name

By clicking Get Connected Now, you agree to be contacted by Asbestos.com’s Patient Advocates with health-related information and services via call, text/SMS using an automated dialing platform and/or email at the telephone number and/or email you provided. Std. msg./data rates apply and your consent to such contact/marketing is not required for purchase of services. You also agree to our Privacy Policy and Terms of Service, including the agreement to arbitrate disputes.

Get Connected Now

Medical Education & Expertise

• H. Lee Moffitt Cancer Center and Research Institute
• Surgery Journal (Reviewer)
• Journal of Surgical Oncology (Reviewer)
• University of Pittsburgh Medical Center (Fellowship)
• National Cancer Institute, NIH (Fellowship)
• State University of New York Buffalo, (M.D.)

Associations, Awards & Recognition

• Society for Surgical Oncologists Presidential Scholar (2026)
• Society for Surgical Oncologists Best Papers Award (2025, for Intra-Tumoral Mucolytic Therapy for Patients with Unresectable Pseudomyxoma Peritonei: Results of an Expanded Access Program) 
• Moffitt Cancer Center CGSO Fellowship Clinical Competency Committee 
• Cancer Biology and Evolution Program, Moffitt Cancer Center (Collaborator)
• Yale Peritoneal Surface Malignancy Consortium 
• Society of Surgical Oncology
• Association for Academic Surgery
• American Association for Cancer Research
• Arnold P. Gold Foundation Humanism and Excellence in Teaching Award (2020)
• Gold Star Award for Excellence in Pediatric Surgery (2020)

Why Choose Dr. Wach for Peritoneal Mesothelioma?

Peritoneal mesothelioma patients who see Dr. Wach benefit from the knowledge and expertise of an active researcher and leader of clinical trials. As an active researcher at Moffitt Cancer Center, he investigates the unique tumor microenvironment of peritoneal mesothelioma and develops novel therapies  and refined surgical approaches specifically for this challenging cancer.

His research focus on improving detection, surveillance and treatment of peritoneal disease directly translates into his approach to patient care. His ongoing work identifying which approaches work best for peritoneal mesothelioma and why informs the personalized treatment plans he develops. This combination of specialized expertise and active innovation means treatment from someone who doesn’t just apply current knowledge but actively advances it to find better ways to prolong survival and alleviate symptoms.

Publications of Dr. Wach

• Wach, M. & Dineen, S. (2025, June 30). ASO Practice Guideline Series: Management of Colorectal Peritoneal Metastases. Retrieved from https://link.springer.com/article/10.1245/s10434-025-17650-w
• Wach, M. et al. (2021, December). Characteristics of Matriculants to Thoracic Surgery Residency Training Programs. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33378696/
• Wach, M. et al. (2020, September). Gallbladder squamous cell carcinoma: An analysis of 1084 cases from the National Cancer Database. Retrieved from https://pubmed.ncbi.nlm.nih.gov/32510655/
• Wach, M. et al. (2020, July). Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31734237/
• Wach, M. et al. (2019, April). Tumor grade and sex should influence the utilization of portal lymphadenectomy for early stage intrahepatic cholangiocarcinoma. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30139566/